5.1 billion, the Chinese medicine equipment was sold! The integration of the Chinese medicine department medical equipment business began

Medical Network July 16th As early as March of this year, it was reported that Sinopharm and Sinopharm's medical device business are seeking mergers, and will seek separate listings to impact A shares.

On July 12, Sinopharm Holding Co., Ltd. (full name of Sinopharm Holding Co., Ltd.) announced that it had purchased China Scientific Equipment Co., Ltd. (hereinafter referred to as 'National Medicine Equipment') from the controlling shareholder Sinopharm Group (full name 'China Pharmaceutical Group Co., Ltd.') 60 % equity, the consideration is 5.108 billion yuan.

Established in 1962, Sinopharm was reorganized into Sinopharm Group in 2009 and reorganized with China Medical Device Industry Corporation in 2010. In 2015, Beijing Natong Shichuang Investment Management Co., Ltd. was introduced as a new legal person shareholder, from national ownership to state-owned holding. , China National Pharmaceutical Group holds 60% of the shares, Beijing Natong holds 40%.

Sinopharm has held and participated in a number of subsidiaries, such as Air Guard General Electric Medical Systems Co., Ltd., Sinopharm Group Financial Leasing Co., Ltd., China Scientific Equipment Import and Export Hunan Co., Ltd., etc. Among them, the most important one is 100% controlled China. Medical Devices Co., Ltd., which is known as the 'National Medicine Device', is the number one circulation enterprise in the medical device industry, achieving revenue of 30.7 billion yuan in 2017.

The buyer Sinopharm is a Hong Kong stock listed company, Sinopharm Group is the de facto largest shareholder, Fosun Pharma is the second largest shareholder, Sinopharm Group and Fosun Pharma are jointly controlled by Sinopharm.

Sinopharm is the number one pharmaceutical circulation enterprise in China, with annual revenue of nearly 280 billion yuan. It is almost the second-ranked China Resources Pharmaceutical and the third-ranked Shanghai Pharmaceuticals. Sinopharm's distribution network covers all provinces and cities across the country. The distribution and logistics distribution capabilities are unquestionable. Sinopharm Group also has its own medical device segment business - 100% controlled Sinopharm Holding Medical Devices Co., Ltd.

Sinopharm is a wholly-owned subsidiary of Sinopharm, and Sinopharm has announced that it will acquire a 60% stake in Sinopharm, and will also include Sinopharm. Sinopharm will become a subsidiary of H-share listed company Sinopharm.

Sinopharm and Sinopharm will be integrated with Sinopharm's original medical device business after it is under the umbrella of Sinopharm. As a result, Sinopharm's original medical device business, Sinopharm equipment business, and Chinese medicine device business will be able to achieve Integrated, all integrated into the pharmaceutical circulation leader of Sinopharm, and a subsidiary of Hong Kong stocks.

This is inconsistent with the previously merged medical device business of Sinopharm and Sinopharm, and the listing of Sinopharm as the main body. There is some inconsistency. Sinopharm has become the main body after the merger.

However, the benefits are also obvious. They are no longer restricted by the state-owned system. Instead, they can use the listing financing ability of Sinopharm to accelerate and expand the enclosure. movement The distribution network with complementary advantages and integration will be stronger. Sinopharm will further enhance its coverage in the medical device distribution market and become the leading leader in the medical device circulation industry. The annual revenue of more than 100 billion yuan is likely to be true. Will be realized.

China's medical device circulation field has not yet ushered in a real policy-intensive period. The two-vote system and circulation reform have not yet been fully rolled out. However, major circulation giants have begun to deploy, grab the period of rapid development opportunities, and upgrade the industry. Market Competitiveness.

Traditional Chinese medicine is moving, China Resources and other traditions medicine Large circulation companies are no exception.

From last year to this year, China Resources medical instruments A series of changes have been made, including a substantial increase in registered capital, cooperation with Syracuse, a consumable reagent intensive service provider, to start a new company, jointly expand the national medical inspection market, etc. China Resources Pharmaceuticals has strategically applied to the previously weak medical device segment business. The intention of reorganization has been highlighted.

At the beginning of this year, Shanghai Pharmaceuticals announced the completion of the acquisition of the Kantler business. The medical device circulation business of Candler China, which has been ranked among the top domestic companies, has been fully integrated into Shanghai Pharmaceuticals.

In 2016, Kyushu has established a supply chain system for orthopedic consumables through continuous construction and mergers and acquisitions. It is reported that its sales in the medical device field in 2017 has reached 15 billion.

In recent years, Ruikang Pharmaceutical has also established a nationwide network of medical device sales and service through continuous mergers and acquisitions. Last year, medical equipment enterprise The revenue is 7.33 billion yuan, and this year's plan is to double the IVD business to 8 billion yuan. Moreover, the company plans to increase the direct sales ratio of the equipment business to over 80% by the end of this year, so that the two-vote system is comprehensive. Meet the preparation.

In addition, Jiashitang has also formed a nationwide high-value consumables distribution network through mergers and acquisitions. Its 25 medical equipment subsidiaries have achieved revenues of 5.1 billion yuan in the first half of this year, and the annual revenue is expected to exceed 10 billion.

The field of medical device circulation has been scattered in the past, and the concentration is not high. Nowadays, the era of oligarchy is really ushered in. The future market must be dominated by oligarchy. Many small and medium-sized medical device circulation enterprises either merge into the oligarchs or form their own Some features, otherwise most will be eliminated.